For Immune System Stem Cell Studies, Mice Aren’t Enough – Science 2.0

For Immune System Stem Cell Studies, Mice Aren't Enough
Science 2.0
The researchers conclude that the humanized mouse model is not suitable for studying the human immune response to transplanted stem cells or cells derived from them. "In an ideal situation, these humanized mice would reject foreign stem cells just as a ...

and more »

Read more from the original source:
For Immune System Stem Cell Studies, Mice Aren't Enough - Science 2.0

North Carolina Advances in Stem Cell Therapy for Lung Diseases Could Lead to Clinical Trial Soon – Lung Disease News

University of North Carolina Health Careresearchers have made strides toward a stem cell treatment for lung diseases such as pulmonary fibrosis, COPD, and cystic fibrosis.

In fact, they are discussing the start of clinical trials with regulatory authorities.

The team discussed its work in two recent studies. One provedthat it is possible to isolate lung stem cells with a relatively non-invasive procedure. The other showed that stem cells reduce fibrosis in rats with pulmonary fibrosis.

The first study, in the journal Respiratory Research, was titledDerivation of therapeutic lung spheroid cells from minimally invasive transbronchial pulmonary biopsies.The second, inStem Cells Translational Medicine, was Safety and Efficacy of Allogeneic Lung Spheroid Cells in a Mismatched Rat Model of Pulmonary Fibrosis.

This is the first time anyone has generated potentially therapeutic lung stem cells from minimally invasive biopsy specimens, Dr. Jason Lobo, director of the universitys lung transplant and interstitial lung disease program,said in a press release. Hewas co-senior author of both studies.

We think the properties of these cells make them potentially therapeutic for a wide range of lung fibrosis diseases, added Dr. Ke Cheng, who led the studies with Lobo. He is anassociate professor in North Carolina State Universitys Department of Molecular Biomedical Sciences.

The research team had previously homed in on stem and support cells they could isolate from a lung tissue sample and grow in a lab. The tissue formed sphere-like structures in a lab dish, prompting the scientists to call them lung spheroid cells.

In 2015, the team showed that these cells had potent regenerative properties in animals with lung diseases. In fact, the stem cells they cultivated outperformed another type called mesenchymal stem cells.

Their latest project involved gathering lung spheroid cells from patients with various lung diseases. They used a procedure calleda transbronchial biopsy thatcan be done in a doctors office.

We snip tiny, seed-sized samples of airway tissue using a bronchoscope, Lobo said. This method involves far less risk to the patient than does a standard, chest-penetrating surgical biopsy of lung tissue.

From this tiny piece of airway, researchers gathered stem cells, then allowed them to multiply because stem cell treatments require infusions of millions of such cells.

When they injected the cells intravenously into mice, the discovered that most found their way into the animals lungs.

These cells are from the lung, and so in a sense theyre happiest, so to speak, living and working in the lung, Cheng said.

The team then tested the treatment in rats exposed to a chemical that triggers lung fibrosis. The lung spheroid cells gave rise to healthy lung cells, reducing both inflammation and fibrosis in the animals lungs.

Also, the treatment was safe and effective whether the lung spheroid cells were derived from the recipients own lungs or from the lungs of an unrelated strain of rats, Lobo said. In other words, even if the donated stem cells were foreign, they did not provoke a harmful immune reaction in the recipient animals, as transplanted tissue normally does.

The researchers said that in humans their goal would be to use patients own stem cells to minimize the risk of immune reactions. But because large quantities of cells are needed, it might be necessary to gather cells from healthy volunteers or organ donation networks as well.

Our vision is that we will eventually set up a universal cell donor bank, Cheng said.

The team is in discussions with the U.S. Food and Drug Administration aimed at starting the first human study by years end. The first trial would include a small group of pulmonary fibrosis patients. The team also hopes their spheroid stem cell therapy will help patients with other lung diseases.

Link:
North Carolina Advances in Stem Cell Therapy for Lung Diseases Could Lead to Clinical Trial Soon - Lung Disease News

Vitamin C Regulates Stem Cell Function – Technology Networks

Not much is known about stem cell metabolism, but a new study from the Childrens Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then regulates their function and suppresses the development of leukemia.

We have known for a while that people with lower levels of ascorbate (vitamin C) are at increased cancer risk, but we havent fully understood why. Our research provides part of the explanation, at least for the blood-forming system, said Dr. Sean Morrison, the Director of CRI.

The metabolism of stem cells has historically been difficult to study because a large number of cells are required for metabolic analysis, while stem cells in each tissue of the body are rare. Techniques developed during the study, which was published in Nature, have allowed researchers to routinely measure metabolite levels in rare cell populations such as stem cells.

The techniques led researchers to discover that every type of blood-forming cell in the bone marrow had distinct metabolic signatures taking up and using nutrients in their own individual way. One of the main metabolic features of stem cells is that they soak up unusually high levels of ascorbate. To determine if ascorbate is important for stem cell function, researchers used mice that lacked gulonolactone oxidase (Gulo) a key enzyme that most mammals, including mice but not humans, use to synthesize their own ascorbate.

Loss of the enzyme requires Gulo-deficient mice to obtain ascorbate exclusively through their diet like humans do. This gave CRI scientists strict control over ascorbate intake by the mice and allowed them to mimic ascorbate levels seen in approximately 5 percent of healthy humans. At these levels, researchers expected depletion of ascorbate might lead to loss of stem cell function but were surprised to find the opposite was true stem cells actually gained function. However, this gain came at the cost of increased instances of leukemia.

Stem cells use ascorbate to regulate the abundance of certain chemical modifications on DNA, which are part of the epigenome, said Dr. Michalis Agathocleous, lead author of the study, an Assistant Instructor at CRI, and a Royal Commission for the Exhibition of 1851 Research Fellow. The epigenome is a set of mechanisms inside a cell that regulates which genes turn on and turn off. So when stem cells dont receive enough vitamin C, the epigenome can become damaged in a way that increases stem cell function but also increases the risk of leukemia.

This increased risk is partly tied to how ascorbate affects an enzyme known as Tet2, the study showed. Mutations that inactivate Tet2 are an early step in the formation of leukemia. CRI scientists showed that ascorbate depletion can limit Tet2 function in tissues in a way that increases the risk of leukemia.

These findings have implications for older patients with a common precancerous condition known as clonal hematopoiesis. This condition puts patients at a higher risk of developing leukemia and other diseases, but it is not well understood why certain patients with the condition develop leukemia and others do not. The findings in this study might offer an explanation.

One of the most common mutations in patients with clonal hematopoiesis is a loss of one copy of Tet2. Our results suggest patients with clonal hematopoiesis and a Tet2 mutation should be particularly careful to get 100 percent of their daily vitamin C requirement, Dr. Morrison said. Because these patients only have one good copy of Tet2 left, they need to maximize the residual Tet2 tumor-suppressor activity to protect themselves from cancer.

Researchers in the Hamon Laboratory for Stem Cell and Cancer Biology, in which Dr. Morrison is also appointed, intend to use the techniques developed as part of this study to find other metabolic pathways that control stem cell function and cancer development. They also plan to further explore the role of vitamin C in stem cell function and tissue regeneration.

This article has been republished frommaterialsprovided byUT Southwestern Medical Center. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Agathocleous, M., Meacham, C. E., Burgess, R. J., Piskounova, E., Zhao, Z., Crane, G. M., . . . Morrison, S. J. (2017). Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature. doi:10.1038/nature23876

Originally posted here:
Vitamin C Regulates Stem Cell Function - Technology Networks

Platelet-rich plasma injections for osteoarthritis of the …

The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Platelet-rich plasma injections for osteoarthritis of the knee, in May 2014.

Osteoarthritis of the knee is the result of progressive deterioration of the articular cartilage and menisci of the joint. Articular cartilage deteriorates because of trauma and wear and tear. This leads to exposure of the bone surface. Symptoms include pain, stiffness, swelling and difficulty walking.

Treatment depends on the severity of the osteoarthritis. Conservative treatments include analgesics and corticosteroid injections to relieve pain and inflammation, and physiotherapy and prescribed exercise to improve function and mobility. When symptoms are severe, surgery may be indicated: options include upper tibial osteotomy and unicompartmental or total knee replacement.

W90.3 Injection of therapeutic substance into joint

Y53.2 Approach to organ under ultrasonic control

Z84.6 Knee joint

X36.8 Other specified blood withdrawal

In addition a code from the ICD-10 category M17 Gonarthrosis [arthrosis of knee] would be recorded.

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

See the original post:
Platelet-rich plasma injections for osteoarthritis of the ...

POINT OF VIEW: Battle opioid crisis by treating pain without narcotics – Palm Beach Post

The misuse of opioids, including prescription pain relievers, has led to an explosion of narcotic addiction and narcotic-related deaths. It is now considered an epidemic. Physicians are thought to be a major contributor to this increase in addiction, as they readily prescribe narcotics for pain relief following injury and surgery, leading to an increase of people who are becoming addicted to these substances. Once physicians stop prescribing these medications, these addicted individuals seek other sources. Of course, the purity and safety of drugs purchased outside the medical-pharmaceutical establishment are additional factors causing injury and death.

There is another way to treat acute injury. The solution is to find alternatives to surgery. Rapid treatment of injuries reduces the inflammation and pain, and avoids the use of narcotics.

Injury initiates an inflammatory response that protects against infection and initiates the healing response. Persistent inflammation, however, causes further tissue damage. Delayed treatment and persistent inflammation cause even further harm to the already injured part of the body.

A recent study of 111 patients compared standard physical therapy and conservative treatments to early injection therapy for acute injury. Thirty percent of the patients had neck injuries, 10 percent had mid-spine injuries and 60 percent had low back injuries. Patients treated more timely had significantly improved outcomes, and most of those treated immediately after injury demonstrated complete recovery. None of the patients medically treated immediately after injury required narcotic medication. This and other recent studies suggest that rapid medical treatment of injuries substantially reduces both the degree of impairment and the amount of narcotic use following accidents and trauma.

Physicians can help stop the opioid crisis by limiting the prescription of pain relievers and looking to other effective treatment options, including laser treatment, platelet rich plasma therapy, steroid injections and other alternatives. As physicians, we need to educate our patients on the importance of rapid treatments, getting to the source of the pain quickly and finding solutions and therapies that address those specific issues directly.

LAWRENCE GORFINE, WEST PALM BEACH

Editors note: Dr. Lawrence Gorfine is president of the Palm Beach Spine & Diagnostic Institute.

See the original post here:
POINT OF VIEW: Battle opioid crisis by treating pain without narcotics - Palm Beach Post

Stem Cell Therapy for Infections by Resilient Bacteria – Financial Tribune

According to data released by the Food and Waterborne Diseases Office of the Health Ministry, an average of 15% of hospital patients suffer from nosocomial infections. A nosocomial infection is an infection acquired in hospital by a patient who was admitted for a reason other than the infection. The severity of hospital-acquired infections depends on the location and type of infection, said Abbasali Imani Fouladi, the scientific secretary of the 18th International Congress of Microbiology, which will be held on Aug. 29-31 at Tehran University of Medical Sciences, ISNA reported. The use of stem cells and their significant role in treatment of the infectionsin particular, antibiotic-resistant infectionsis a key topic that will be discussed by domestic and foreign specialists at the conference. Sometimes ulcers which are resistant to conventional treatment, respond positively and swiftly to stem cell treatments, he explained, adding that officials from Council for Stem Cell Sciences and Technologies (affiliated to Vice-Presidency for Science and Technology) have been invited to the event that will be attended by scientists from Spain, Italy, UK, and France. Four workshops will be held on the sidelines of the meeting. Stating that with resistance to antibiotics becoming more common, there is greater need for alternative treatments, he said, Currently there are 12 strains of bacteria in need of new antibiotics or alternative treatments. The event is co-sponsored by the Health Ministry, TUMS, Pasteur Institute of Iran, Razi Vaccine and Serum Research Institute, and Ilam University of Medical Sciences, according to the congress website (ismcongress.ir). Nosocomial infections occur worldwide and affect both developed and resource-poor countries. Healthcare-associated infections are among the major causes of death and increased morbidity among hospitalized patients. They are a significant burden both for the patient and public health. According to the World Health Organization, HAIs add to functional disability and emotional stress of the patient and may in some cases, lead to disabling conditions that reduce the quality of life. Nosocomial infections are also one of the leading causes of death. The economic costs are considerable. The increased length of hospital stay for infected patients is the greatest contributor to cost. While the prevalence rate of HAIs is 30% in lower-income countries, the average rate is around 6-11% in developed countries, according to Dr. Hossein Masumi-Asl, head of the Food and Waterborne Diseases Office. The most frequent nosocomial infections are infections of surgical wounds, urinary tract infections and lower respiratory tract infections, he said. According to the official, the highest prevalence of nosocomial infections occurs in intensive care units and in acute surgical and orthopedic wards. Infection rates are higher among patients with increased susceptibility because of old age, underlying disease, or chemotherapy.

Originally posted here:
Stem Cell Therapy for Infections by Resilient Bacteria - Financial Tribune

Weill Cornell Medicine Qatar scientists create blood in the laboratory – The Peninsula Qatar

22 Aug 2017 - 1:44

Dr Rafii Tabrizi and Dr Jennifer Pasquier.

Researchers at Weill Cornell Medicine Qatar (WCM-Q) have made a breakthrough which could lead to personalized blood and heart tissue being created in a laboratory.

Working with colleagues from the Ansary Stem Cell Institute at Weill Cornell Medicine in New York, researchers in the laboratory of Dr Arash Rafii Tabrizi at WCM-Q in Doha postulated that endothelial cells the cells that line the walls of blood vessels are responsible for organ development.

Dr Rafii Tabrizi, whose work has been funded by Qatar National Research Fund, said: We hypothesized that the endothelial cells are the masterminds of organ development and different organs have different endothelial cells that express different and specific factors called angiocrine factors that lead to the development and function of the organ.

To test the theory, Dr Tabrizi and his team isolated endothelial cells and forced the expression of transcription factors using DNA vectors.

After 20 days, the cells began to multiply and were essentially transformed into hematopoietic stem cells, which are the basis for all types of blood cells, including red blood cells, platelets, and white blood cells, which are a vital part of the immune system.

Dr Tabrizi, who is Associate Professor of Genetic Medicine in Obstetrics and Gynaecology at WCM-Q, said that the next step would be to translate the research to a human model, to test whether the findings can be translated to tackle different human diseases.

Dr Tabrizi said: If you have leukemia, for example, we would retrieve your endothelial cells and we could transform that into blood. It would be an unlimited personal source of blood for each individual. However, it is too early at this stage to make these assumptions in the absence of concrete human data

Importantly the power of the endothelium to support cellular differentiation for blood cells is also successful with cardiac cell regeneration. By combining endothelial cells with cardiomyocytes the hearts muscle cells the researchers were able to create muscle cells in a petri dish that beat together in a regular rhythm, similar to endogenous cardiomyocytes.

Dr Jennifer Pasquier, Research Associate in Genetic Medicine at WCM-Q who performed these experiments said: Some organs function to secrete substances so, for example pancreatic cells would have to be sensitive to blood sugar levels and secrete insulin. But for cardiac cells we want them to integrate and beat in synchrony with each other. The problem is, if you transplant cardiac cells into your heart and then they beat at a different rate from the other cells, this would be the catastrophic for the individual.

21 Aug 2017 - 1:58

Qatars future doctors have taken the symbolic first step towards their chosen career by donning the white coat of the physician.

The rest is here:
Weill Cornell Medicine Qatar scientists create blood in the laboratory - The Peninsula Qatar

This Chip Uses Electricity to Reprogram Cells for Healing – Singularity Hub

It sounds like science fiction: with a light zap of electricity, a tiny stamp-like device transforms your skin cells into reservoirs of blood vessels or brain cells, ready to heal you from within.

Recently, a team of medical mavericks at the Ohio State University introduced a device that does just that. The technology, dubbed tissue nanotransfection (TNT), is set to blow up the field of organ regeneration.

When zapped with a light electrical jolt, the device shoots extra bits of DNA code from its nanotube arrays directly into tiny pores in the skin. There, the DNA triggers the cells to shed their identity and reprograms them into other cell types that can be harvested to repair damaged organs.

Remarkably, the effect spreads with time. The rebooted cells release tiny membrane bubbles onto their neighboring skin cells, coaxing them to undergo transformation. Like zombies, but for good.

So far, the device has already been used to generate neurons to protect the brains of mice with experimental stroke. The team also successfully healed the legs of injured mice by turning the skin cells on their hind limbs into a forest of blood vessels.

While still a ways from human use, scientists believe future iterations of the technology could perform a myriad of medical wonders: repairing damaged organs, relieving brain degeneration, or even restoring aged tissue back to a youthful state.

By using our novel nanochip technology, injured or compromised organs can be replaced. We have shown that skin is a fertile land where we can grow the elements of any organ that is declining, says lead author Dr. Chandan Sen, who published the result in Nature Nanotechnology.

In my lab, we have ongoing research trying to understand the mechanism and do even better, adds Dr. L. James Lee, who co-led the study with Sen. So, this is the beginning, more to come.

The Ohio teams research builds on an age-old idea in regenerative medicine: that even aged bodies have the ability to produce and integrate healthy, youthful cellsgiven the right set of cues.

While some controversy remains on whether replacement cells survive in an injured body, scientistsand some rather dubious clinicsare readily exploring the potential of cell-based therapies.

All cells harbor the same set of DNA; whether they turn into heart cells, neurons, or back into stem cells depend on which genes are activated. The gatekeeper of gene expression is a set of specialized proteins. Scientists can stick the DNA code for these proteins into cells, where they hijack its DNA machinery with orders to produce the protein switchesand the cell transforms into another cell type.

The actual process works like this: scientists harvest mature cells from patients, reprogram them into stem cells inside a Petri dish, inject those cells back into the patients and wait for them to develop into the needed cell types.

Its a cumbersome process packed with landmines. Researchers often use viruses to deliver the genetic payload into cells. In some animal studies, this has led to unwanted mutations and cancer. Its also unclear whether the reprogrammed stem cells survive inside the patients. Whether they actually turn into healthy tissue is even more up for debate.

The Ohio teams device tackles many of these problems head on.

Eschewing the need for viruses, the team manufactured a stamp-sized device out of silicon that serves as a reservoir and injector for DNA. Microetched onto each device are arrays of nanochannels that connect to microscopic dents. Scientists can load DNA material into these tiny holding spots, where they sit stably until a ten-millisecond zap shoots them into the recipients tissue.

We based TNT on a bulk transfection, which is often used in the lab to deliver genes into cells, the authors explain. Like its bulk counterpart, the electrical zap opens up tiny, transient pores on the cell membrane, which allows the DNA instructions to get it.

The problem with bulk transfection is that not all genes get into each cell. Some cells may get more than they bargained for and take up more than one copy, which increases the chance of random mutations.

We found that TNT is extremely focused, with each cell receiving ample DNA, the authors say.

The device also skips an intermediary step in cell conversion: rather than turning cells back into stem cells, the team pushed mouse skin cells directly into other mature cell types using different sets of previously-discovered protein factors.

In one early experiment, the team successfully generated neurons from skin cells that seem indistinguishable from their natural counterparts: they shot off electrical pulses and had similar gene expression profiles.

Surprisingly, the team found that even non-zapped cells in the skins deeper layers transformed. Further testing found that the newly reprogrammed neurons released tiny fatty bubbles that contained the molecular instructions for transformation.

When the team harvested these bubbles and injected them into mice subjected to experimental stroke, the bubbles triggered the brain to generate new neurons and repair itself.

We dont know if the bubbles are somehow transforming other brain cell types into neurons, but they do seem to be loaded with molecules that protect the brain, the researchers say.

In an ultimate test of the devices healing potential, the researchers placed it onto the injured hind leg of a handful of mice. Three days prior, their leg arteries had been experimentally severed, whichwhen left untreatedleads to tissue decay.

The team loaded the device with factors that convert skin cells into blood vessel cells. Within a week of conversion, the team watched as new blood vessels sprouted and grew beyond the local treatment area. In the end, TNT-zapped mice had fewer signs of tissue injury and higher leg muscle metabolism compared to non-treated controls.

This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time, says Sen.

A major draw of the device is that its one-touch-and-go.

There are no expensive cell isolation procedures and no finicky lab manipulations. The conversion happens right on the skin, essentially transforming patients bodies into their own prolific bioreactors.

This process only takes less than a second and is non-invasive, and then youre off. The chip does not stay with you, and the reprogramming of the cell starts,says Sen.

Because the converted cells come directly from the patient, theyre in an immune-privileged position, which reduces the chance of rejection.

This means that in the future, if the technology is used to manufacture organs immune suppression is not necessary, says Sen.

While the team plans to test the device in humans as early as next year, Sen acknowledges that theyll likely run into problems.

For one, because the device needs to be in direct contact with tissue, the skin is the only easily-accessible body part to do these conversions. Repairing deeper tissue would require surgery to insert the device into wounded areas. And to many, growing other organ cell types is a pretty creepy thought, especially because the transformation isnt completely localnon-targeted cells are also reprogrammed.

That could be because the body is trying to heal itself, the authors hypothesize. Using the chip on healthy legs didnt sprout new blood vessels, suggesting that the widespread conversion is because of injury, though (for now) there isnt much evidence supporting the idea.

For another, scientists are still working out the specialized factors required to directly convert between cell types. So far, theyve only had limited success.

But Sen and his team are optimistic.

When these things come out for the first time, its basically crossing the chasm from impossible to possible, he says. We have established feasibility.

Image Credit: Researchers demonstrate tissue nanotransfection,courtesy of The Ohio State University Wexner Medical Center.

Read the rest here:
This Chip Uses Electricity to Reprogram Cells for Healing - Singularity Hub

New tool for cell-free therapy based on artificial membrane vesicles – Medical Xpress

August 22, 2017

Scientists at Kazan Federal University's Institute of Fundamental Medicine and Biology, led by Professor Albert Rizvanov, have shown that artificial membrane vesicles generated by Cytochalasin B treatment of human cells retain angiogenic activity.

Vesicles are small packages of material released from cells and act to deliver cargo and messages to adjacent and distant cells. Vesicles are known to be important regulators of normal physiology and have also been implicated in disease, notably cancer. Extracellular vesicles exhibit the biological activity of the cell from which they originate. For example, extracellular vesicles of stem cells are able to promote angiogenesis and regeneration. For this reason, extracellular vesicles represent a promising tool for cell-free therapy to deliver biologically active molecules.

However, the yield of naturally occurring vesicles is too low for practical purposes. Recently, several studies demonstrated the ability to generate a large number of membrane vesicles from cultured cells treated with a drug, Cytochalasin B. This cost-effective approach permits the generation of large quantities of extracellular vesicles. However, it remained unknown whether these Cytochalasin B-induced micro-vesicle (CIMVs) retained characteristic biological properties of their parental cells.

To address this, an international team of investigators, led from Kazan Federal University, Russia by Professor Albert Rizvanov, with international collaborators, characterized the biological activity of membrane vesicles.

The study was published in Oncotarget. The lead author, Dr. Marina Gomzikova, and colleagues described the morphology, molecular composition, fusion capacity and biological activity of Cytochalasin B-induced membrane vesicles (CIMVs). This data suggests that the biophysical, molecular and size distribution properties of CIMVs are similar to natural vesicles. Furthermore, they demonstrated that CIMVs retain the biological properties of the donor cells, as they can stimulate angiogenesis in vitro and in vivo.

CIMVs can now be produced in large quantities and scaled to an industrial production level; potential therapeutic applications to deliver biologically active molecules of CIMVs are now possible.

Explore further: Insulin release is controlled by the amount of Epac2A at the secretory vesicles

More information: Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells. Oncotarget. doi.org/10.18632/oncotarget.19723

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post:
New tool for cell-free therapy based on artificial membrane vesicles - Medical Xpress

Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to … – Business Wire (press release)

SAN CARLOS, Calif.--(BUSINESS WIRE)--Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, today announced it has been awarded a grant from the California Institute for Regenerative Medicine (CIRM) for up to $6.86 million to support preclinical development and the filing of an Investigational New Drug application (IND) for CLT030-ADC, Cellerants antibody-drug conjugate (ADC) product for the treatment for acute myeloid leukemia (AML). AML is an aggressive cancer with high relapse rates and low overall survival, which are thought to be due to the persistence of leukemic stem cells that are relatively resistant to current chemotherapy regimens. CLT030-ADC targets C-type-like lectin 1 (CLL1), a cell surface antigen highly expressed on leukemic stem cells but not on normal hematopoietic stem and progenitor cells.

CIRM is an agency of the State of California whose mission is to accelerate stem cell treatments to patients with unmet medical needs. CIRM grants are awarded through a competitive process which includes rigorous review and evaluation by independent scientific and medical experts.

"We are honored to receive this award from CIRM, which will help us advance the development of CLT030-ADC, said Ram Mandalam, Ph.D., President and Chief Executive Officer of Cellerant. Based on target characteristics and preclinical results, CLT030-ADC has the potential to increase survival and become a first-in-class treatment for AML patients. We are excited to be working with CIRM to develop this novel therapeutic for an unmet medical need.

Our mission here at CIRM is to support novel stem cell-based therapeutics, including those that target cancer stem cells, added Maria Millan, M.D., interim President and CEO of CIRM. Cancer stem cells are believed to play a key role in tumor formation and growth, so attacking them has the potential to improve patient outcomes in deadly diseases such as AML.

CLT030-ADC consists of an antibody targeting CLL1 linked to a DNA-damaging cytotoxic payload. CLL1 is an antigen expressed specifically on AML cancer stem cells and not on normal hematopoietic stem cells. The Company and others have shown that CLL1 is expressed in approximately 90% of all AML patient types, including all French American British classifications, all cytogenetic risk categories, and in patients independent of FLT-3 status. In preclinical AML models, CLT030-ADC demonstrated complete target-dependent tumor regression. Importantly, CLT030-ADC should have minimal effect on the formation of

normal blood cell types because CLL1 is not expressed on normal hematopoietic stem cells and minimally on progenitor cells. This would potentially be an important safety advantage compared to other targeted therapies for AML where the target antigen is expressed on normal stem and progenitor cells, such as CD33.

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerants CLT-008 (human myeloid progenitor cells) is a universal cell therapy for the treatment of neutropenia. Chemotherapy-induced neutropenia is a severe side effect of many chemotherapy regimens, particularly for AML and other hematologic malignancies. CLT-008 is currently in a randomized, controlled Phase 2 clinical trial in patients with AML. Cellerants is developing two antibody drug-conjugate (ADC) product candidates: CLT030-ADC, intended to treat AML by selectively targeting and killing leukemic stem and blast cells, and CLT012-ADC, which could be a potential treatment for AML and a number of solid tumors. For more information, visit: http://www.cellerant.com

View post:
Cellerant Therapeutics, Inc. Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to ... - Business Wire (press release)